Subtype
Skin Basal Cell Carcinoma
CI-CAN-00003940BCCExplore in graph →
17 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003940BCCExplore in graph →
Clinical trials
83 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03180528 | Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | completed | Phase 2 | 30 | Kavita SarinOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02699723 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | withdrawn | Early Phase 1 | 0 | Jean Yuh TangOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT01806675 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
| completed |
| Phase 1 / Phase 2 |
| 25 |
| Sanjiv Sam GambhirOTHER |
| 1 |
| Oct 3, 2019 |
| clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02735356 | Topical Itraconazole in Treating Patients With Basal Cell Cancer | completed | Early Phase 1 | 9 | Jean Yuh TangOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02690948 | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | completed | Phase 1 / Phase 2 | 16 | Anne ChangOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02270645 | Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser(BCC) | completed | N/A | 12 | University of MiamiOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03621462 | Elucid Labs AIDA™ - Labelled Image Acquisition Protocol | unknown | N/A | 4,000 | Elucid Labs Inc.INDUSTRY | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01791894 | Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma(ATO) | completed | Phase 1 / Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma(ASN-002-001) | completed | Phase 1 / Phase 2 | 16 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02007317 | Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study | completed | Phase 2 | 30 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT03012009 | Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial | completed | N/A | 16 | University Hospital, GhentOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT01631331 | Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) | completed | Early Phase 1 | 15 | Stanford UniversityOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT01325688 | PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | completed | Phase 2 | 75 | PeplinINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00432185 | To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | completed | Phase 2 | 117 | PeplinINDUSTRY | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma | withdrawn | N/A | 0 | Albert Einstein College of MedicineOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | terminated | N/A | 85 | University of Wisconsin, MadisonOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT01292668 | Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer | completed | Phase 1 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT01491711 | Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate | unknown | Phase 4 | 162 | Maastricht University Medical CenterOTHER | 1 | Jan 31, 2014 | clinicaltrials |
| NCT02018679 | Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 1 | 34 | Dong-A UniversityOTHER | 1 | Dec 23, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01155609 | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer | completed | N/A | 10 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00023959 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT01637194 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | completed | Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00189306 | Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream | completed | Phase 3 | 169 | Graceway Pharmaceuticals, LLCINDUSTRY | 2 | Aug 10, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2021source: clinicaltrials